Wei Guo Su
Chief Executive Officer chez HUTCHMED (CHINA) LIMITED
Fortune : 16 M $ au 31/03/2024
Postes actifs de Wei Guo Su
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| HUTCHMED (CHINA) LIMITED | Director/Board Member | 27/03/2017 | - |
| Chief Executive Officer | 04/03/2022 | - | |
| Chief Tech/Sci/R&D Officer | 01/01/2012 | - | |
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Chief Tech/Sci/R&D Officer | 24/03/2010 | - |
Historique de carrière de Wei Guo Su
Anciens postes connus de Wei Guo Su
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
Formation de Wei Guo Su
| Harvard University | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Chine | 3 |
| Hong Kong | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| HUTCHMED (CHINA) LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
- Bourse
- Insiders
- Wei Guo Su
- Expérience
